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Abstract
Background: In the emergency setting, non-traumatic headache is a benign symptom in 80% of cases, but serious
underlying conditions need to be ruled out.
Copeptin improves risk stratification in several acute diseases. Herein, we investigated the value of copeptin to
discriminate between serious secondary headache and benign headache forms in the emergency setting.
Methods: Patients presenting with acute non-traumatic headache were prospectively enrolled into an observational
cohort study. Copeptin was measured upon presentation to the emergency department. Primary endpoint was serious
secondary headache defined by a neurologic cause requiring immediate treatment of the underlying disease.
Secondary endpoint was the combination of mortality and hospitalization within 3 months. Two board-certified
neurologist blinded to copeptin levels verified the endpoints after a structured 3-month-telephone interview.
Results: Of the 391 patients included, 75 (19%) had a serious secondary headache. Copeptin was associated
with serious secondary headache (OR 2.03, 95%CI 1.52–2.70, p < 0.0001). Area under the curve (AUC) for
copeptin to identify the primary endpoint was 0.70 (0.63–0.76). After adjusting for age > 50, focal-neurological
abnormalities, and thunderclap onset of symptoms, copeptin remained an independent predictive factor for
serious secondary headache (OR 1.74, 95%CI 1.26–2.39, p = 0.001). Moreover, copeptin improved the AUC of the
multivariate logistic clinical model (p-LR-test < 0.001).
Even though copeptin values were higher in patients reaching the secondary endpoint, this association was not
significant in multivariate logistic regression.
Conclusions: Copeptin was independently associated with serious secondary headache as compared to benign
headaches forms. Copeptin may be a promising novel blood biomarker that should be further validated to rule
out serious secondary headache in the emergency department.
Trial registration: Study Registration on 08/02/2010 as NCT01174901 at clinicaltrials.gov.
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Background
Headache has a high prevalence in the general population
and presents an important public health problem [1].
Non-traumatic headache has a prevalence of 0.5 to
4.5% in patients presenting to the emergency depart-
ment (ED), and it remains a major diagnostic challenge
[2–5]. The majority of these patients have benign head-
ache. However, in 3.8 – 20% of headache patients, a
headache secondary to a potentially life-threatening con-
dition is diagnosed with immediate implications for
therapeutic interventions. These include subarachnoidal
hemorrhage, cerebral aneurysm, intracranial bleeding,
sinus vein thrombosis, temporal arteriitis, or meningitis
[2, 5–7]. It has been shown by various authors that red
flags like age >50 years, focal-neurological signs, thun-
derclap onset of symptoms or altered mental status have
a remarkable negative predictive value around 0.98–0.99,
however with varying sensitivities (between 0.39 and
100%) and specificities (between 65 and 98%) [7–11]. To
improve the differentiation of benign headaches from
secondary, potentially serious headache forms, various
clinical algorithms which include these red flags have
been proposed, but they are only inconsistently applied
in clinical practice [7, 12]. Therefore, the use of bio-
markers has potential merits as diagnostic tools.
Only few biomarkers have been investigated in head-
ache, [13–22] and except D-dimer in specific vascular
etiologies, [14, 17] they have not found their way into
emergency algorithms. To our knowledge, there is no
data on biomarkers for discriminating between serious
secondary and benign headache forms.
Copeptin is a hypothalamic stress hormone that mir-
rors the individual stress level even more subtly than
circulating cortisol [23]. In its function as a stress hor-
mone, copeptin serves as a prognostic marker in various
acute disease states, such as cerebrovascular event, myo-
cardial infarction or pneumonia [24]. Apparently, copep-
tin allows tapping an endogenous information system of
our body that, through mechanisms still poorly under-
stood, assesses the severity of damage [25].
We herein prospectively evaluated the use of copeptin
for discriminating between benign headache forms and
serious secondary headache, and the degree of associ-
ation with serious secondary headache.
Methods
Study design and participants
This multicenter observational study was performed at
the ED of two tertiary care hospitals in northern
Switzerland from October 2010 to March 2013.
All patients with current non-traumatic headache as a
chief complaint presenting to the ED or as an emergency
to the medical or neurological walk-in clinic of the two
tertiary centers were eligible and screened.
Exclusion criteria were trauma within 7 days, chronic
headache defined as > 3 months duration, age < 18 years,
missing informed consent, and inability to comply with
study procedures due to insufficient knowledge of the
German language.
Chronic headache with an acute exacerbation was not
an exclusion criterion.
Clinical variables
Recruitment was during 24 h and on weekdays and
weekends.
After informed consent was given by the patient,
baseline data were assessed by questionnaire at the time
of the acute presentation. This included medical his-
tory, age, gender, body mass index, ethnicity and coun-
try of origin, past medical history, smoking history,
current medication, alcohol and coffee consumption
(units per day), and substance abuse. Clinical headache
presentation and headache history was assessed by de-
tailed standardized, validated questionnaire containing the
International Classification of Headache Disorders (ICHD)
[26] and included depression screening by Primary Care
Evaluation of Mental Disorders (PRIME-MD) question-
naire [27] and categorization by a validated, diagnostic
algorithm into one of four clinical scenarios (Thunder-
clap headache, meningitis, new or worsening headache,
headache similar to previous episodes) as described by
Grimaldi et al. [7]. Disease severity, quality of daily liv-
ing, and interference of symptoms with quality of life
was assessed using the standardized, validated migraine
disability assessment (MIDAS) [28].
Clinical items assessed by the treating physician were
recorded at the time of the acute presentation and in-
cluded physical examination, neurological assessment,
Glasgow Coma Scale, blood pressure, pulse rate, and
body temperature.
Blood sampling and assays
Blood samples for copeptin measurement were drawn
on admission in the emergency department and were ei-
ther obtained from an indwelling venous catheter or by
venous puncture. Blood samples were immediately cen-
trifuged and stored in the refrigerator. Apart from blood
sampling for study purposes, routine blood sampling
was performed at the discretion of the treating physi-
cians and was performed in 354 (91%) patients.
At ED discharge, the diagnostic work-up was recorded,
including neuroimaging, lumbar puncture and additional
disease-specific evaluations in secondary headaches.
Blood Plasma was frozen at −70 °C. Copeptin levels
were measured by batch analysis with a commercial
chemiluminescence sandwich immunoassay (B.R.A.H.M.S
LUMItest CT-proAVP, B.R.A.H.M.S AG, Hennigsdorf/
Berlin, Germany), as described in detail elsewhere, with a
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lower detection limit of the assay of 0.4 pmol/L and the
functional assay sensitivity (<20% interassay CV) of < 1
pmol/L) [29, 30]. The treating physicians and the study
team were blinded to copeptin levels at all times.
Follow-up
At 3 months, a structured follow-up telephone interview
was performed to assess course and outcome of the dis-
ease. The earliest possible contact was 14 days before
this time point. If the patient was not reached until 4
weeks after the scheduled interview, his primary care
physician was contacted for follow-up information. If
the patient had consulted the hospital since study inclu-
sion and no other data was available, this date was taken
as time of last follow-up. To minimize loss of follow-up,
the study team tried to re-contact the patient until the
last scheduled follow-up interview in June 2013. The
final headache diagnosis and the judgement whether the
headache had been serious or not was made in each pa-
tient after the follow-up interview by two independent
physicians by chart review and verified by a board-
certified neurologist. Disagreements between study
physicians were resolved by a final adjudication of an
independent neurologist. They were all blinded to
copeptin levels.
Outcomes
The objective of this study was to evaluate copeptin as a
marker for risk stratification in non-traumatic headache,
namely for ruling out serious secondary causes of head-
ache. The primary endpoint was serious secondary head-
ache as opposed to benign headache.
Our hypothesis was that based on previous studies on
copeptin in other diseases, [29, 31–34] a cutoff of ≤ 5
pmol/l would have a sensitivity of ≥ 97% for ruling out
serious secondary headache causes, and that a cutoff
of ≥ 20 pmol/l would have a specificity of ≥90% for the
presence of serious secondary NTH.
The secondary endpoint was the combined endpoint
of death or hospitalization of any cause within 3 months.
Headache was defined according to the International
Headache Society as pain located above the orbitomeatal
line. A serious secondary headache was defined as a
headache with a neurologic cause as listed in the ICHD-
II criteria [9] requiring subsequent treatment of the
underlying disease or condition, which, if left untreated,
would have the potential risk of permanent damage or
death(see also Appendix). All other patients with an un-
eventful 3-month follow-up were diagnosed with benign
headache.
Our gold standard for the final diagnosis of headache
was the clinical diagnosis according to ICHD-II criteria
after 3 months, verified by a board-certified neurologist.
Headaches which clearly belonged to the primary
headache entities but did not fulfill the full diagnostic
criteria were classified as “primary headache, not classi-
fied”, e.g. a first episode of migraine, which did not yet
fulfill the criterion of at least 3 episodes.
As this study was started before the current version
ICHD3-beta was in place, we continued to use the
ICHD-II classification for consistency throughout the
whole study.
Analysis
Discrete variables are summarized as counts (percent-
age), and continuous variables as medians and interquar-
tile ranges(IQRs). Frequency comparison was done by
chi-square test. Two-group comparisons of continuous
variables were performed using Student’s t-test or the
Mann–Whitney-U test, depending on their distribution.
Receiver operating characteristic (ROC) curve for copep-
tin was calculated, and the area under the ROC curve
(AUC) was used to assess the discriminatory potential of
copeptin to accurately identify patients with serious
secondary headache [35]. Further, we calculated logistic
regression models to estimate the magnitude of the asso-
ciation between copeptin and the pre-specified end-
points. To assess the independence of this association
from other risk scores and important outcome predic-
tors (chosen from the published literature) we calculated
multivariable regression models and added all parame-
ters based on their association in the univariate models
(p-value cut off for further evaluation was <0.05). This
included age > 50 years, sudden onset of headache, an
abnormal neurological examination, [11] clinical sce-
nario 4 (history of previous similar headache) for the
clinical model (multivariate model 1), [7] D-dimer, fi-
brinogen, leukocytes and C-reactive protein [13, 36] for
the laboratory model (multivariate model 2). To avoid
overfitting, we calculated two final models, thus no more
than one variable per ten events were included in these
final two models. In addition, we compared the ROC
curves based on the logistic models with and without
copeptin using the likelihood ratio test [37]. All statis-
tical tests were 2-tailed. p < 0.05 was considered signifi-
cant. STATA 12.1 (StataCorp LP, College Station, TX,
USA) was used for data analysis.
Sample size considerations
Based on the patient numbers from previous years,
about 400 patients per year were estimated to be eligible
for this study. With an estimated informed consent rate
of 90–95% and an estimated loss of follow-up of 5–10%,
360 patients were estimated to complete the study. Ac-
cording to pre-existing literature, 10–20% of these 360
patients would present with serious non-traumatic head-
ache, thus 50–60 patients would reach the primary end-
point. Based on the literature and pilot data [25], a mean
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copeptin difference of 15 pmol/L (SD of 30 pmol/L) be-
tween these groups was expected. This difference would
be detected with a power of 80%.
Results
Characteristics of study subjects
From October 2010 to March 2013, 398 patients were
enrolled into the CoHead-Study (see Fig. 1 for study
flow chart). The 3-month telephone interviews were ter-
minated in July 2013. 7 patients were lost to follow-up
and were therefore not included in the analysis.
Baseline characteristics are shown in Table 1. Median
age was 41 (IQR 30–57), 146 patients (37%) were men.
Median headache duration was 3 days (IQR 0.5–7); me-
dian pain strength on Visual Analogue Scale (VAS) was
8 (IQR 6–9). At discharge, a primary headache form
was diagnosed in 219 (56%) patients, and secondary
headache in 172 (44%) patients, of which 75 (19.2%)
were classified as serious.
The group of serious secondary headache was
heterogeneous: 8 patients (2%) had subarachnoidal
hemorrhage, 7 (1.8%) sinus vein thrombosis, 10 (2.6%)
intracranial bleeding, and 7 (1.8%) had viral meningitis
(detailed diagnoses are shown in Table 2).
Median time to follow-up was 99 days (IQR 91–118;
range 9–632). Two patients (0.5%) died during follow-
up. Both had initially presented with serious secondary
headache: one with subarachnoidal bleeding and one
with bacterial meningitis. Hospitalization rate was 94 pa-
tients (24.0%), of which 61 (15.6%) were hospitalized im-
mediately following study inclusion.
Main results
Association of copeptin with serious secondary headache
Copeptin levels were higher in serious secondary headache
forms as compared to all other headache forms (median
6.44 pmol/L (IQR 3.97–11.29) vs. 3.89 pmol/L (IQR 2.59–
6.10)(p < 0.0001), see Fig. 2). The AUC for copeptin to de-
tect serious secondary headache was 0.70 (95% confidence
interval (CI) 0.63–0.76). At the predefined rule-out cutoff
for serious secondary headache of 5.0 pmol/L, copeptin had
a sensitivity of 64.4%; at the predefined rule-in cutoff of 20
pmol/L, copeptin had a specificity of 95.3% to rule in a ser-
ious secondary headache. At the cutoff of 2.5 pmol/L,
copeptin had a sensitivity of 91.8% to rule out serious sec-
ondary headache, i.e. a negative predictive value of 0.93. For
different copeptin cutoffs, see Table 3.
In univariate analysis, copeptin was associated with ser-
ious secondary headache with an OR of 2.03 (95%CI 1.52–
2.70, p < 0.0001). Other strong predictors were age >50 years
(OR 2.83, 95%CI 1.69–4.74, p < 0.0001), an abnormal
neurological exam (OR 3.50, 95%CI 1.99–6.14, p < 0.0001),
and thunderclap onset of symptoms (OR 4.23, 95%CI 2.38–
7.52, p < 0.0001; for detailed results of the univariate ana-
lysis, see Table 4a).
We included the strongest clinical risk factors from
the univariate analysis along with copeptin in a multi-
variate model. After adjustment, copeptin remained
independently associated with serious secondary head-
ache (OR 1.74, 95%CI 1.26–2.39, p = 0.001). The clin-
ical factors age > 50 years (OR 2.25, 95%CI 1.28–3.96),
male gender (OR 1.84, 95%CI 1.27–3.52), focal-
neurological findings (OR 2.63, 95%CI 1.99–6.14), and
thunderclap onset (OR 2.89, 95%CI 2.38–7.52) also
remained associated with serious secondary headache
(for detailed values, see Table 4b).
Moreover, copeptin improved the AUC of the
multivariate logistic clinical model (model without
copeptin: AUC 0.735 (95%CI 0.664–0.807), model
with copeptin: AUC 0.7544 (95% CI0.683–0.825), p-
LR-test < 0.001).
In a second multivariate model, laboratory values
including fibrinogen, leukocytes and copeptin were
assessed. Only copeptin remained associated with ser-
ious secondary headache (OR 1.80, 95%CI 1.33–2.44,
p < 0.0001; for detailed values, see Table 4c).
Fig. 1 STROBE study flow diagram
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Association of copeptin with mortality or hospitalization
In the 94 (24.0%) patients reaching the composite end-
point death or hospitalization of any cause within
3 months, copeptin values were higher as compared to
patients without these events (median 6.44 pmol/L(IQR
3.97–11.29) vs. 3.89 (IQR 2.59–6.01; p = 0.0006). The
AUC for the composite endpoint was 0.62 (95%CI 0.56-
0.68). In univariate logistic regression analysis, copeptin
was a predictor for the composite endpoint (OR 1.45,
95%CI 1.12–1.88, p = 0.005).
Other strong predictors were age > 50 years (OR 2.77,
95%CI 1.72–4.46), an abnormal neurologic exam (OR
4.23, 95%CI 2.47–7.24), thunderclap onset of headache
(OR 3.04, 95%CI 1.75–5.29), clinical scenario 4 (history
Table 1 Baseline characteristicsa






Age (years) 41 (30 – 57) 39 (28 – 54) 56 (40 – 66)
Male sex 146 (37.3%) 107 (33.9%) 39 (52.0%)
Comorbidities
Hypertension 51 (13.0%) 36 (11.4%) 15 (20.0%)
Coronary heart disease 17 (4.3%) 8 (2.5%) 9 (12.0%)
Atrial fibrillation 2 (0.5%) 1 (0.3%) 1 (1.3%)
Cerebrovascular ischemic disease 2 (0.5%) 0 2 (2.7%)
Chronic obstructive lung disease 1 (0.3%) 1 (0.3%) 0
Multiple sclerosis 2 (0.5%) 2 (0.6%) 0
Chronic pain syndrome 7 (1.8%) 6 (1.9%) 1 (1.3%)
Depression 17 (4.3%) 16 (5.1%) 1 (1.3%)
Epilepsy 9 (2.3%) 3 (0.9%) 6 (8.0%)
Associated headache symptoms
Nausea 214 (54.7%) 178 (56.3%) 36 (48.0%)
Vomiting 106 (27.1%) 83 (26.3%) 23 (30.7%)
Visual aura 124 (31.7%) 107 (33.9%) 17 (22.7%)
Photophobia 190 (48.6%) 160 (50.6%) 30 (40.0%)
Thunderclap onset headache 67 (17.1%) 39 (12.3%) 28 (37.3%)
Nuchal rigidity 10 (2.6%) 6 (1.9%) 4 (5.3%)
Scenariob
1: Worst headache ever 67 (17.1%) 39 (12.3%) 28 (37.3%)
2: fever/neck stiffness 26 (6.6%) 21 (6.6%) 5 (6.7%)
3: recent worsening 169 (43.2%) 141 (44.6%) 28 (37.3%)
4: history of previous similar headache 112 (28.6%) 99 (31.3%) 13 (17.3%)
5: none of the above 17 (4.3%) 16 (5.1%) 1 (1.3%)
Clinical findings
Systolic blood pressure (mmHg) 134 (121 – 148) 131 (120 – 145) 139 (125 – 159)
Diastolic blood pressure (mmHg) 80 (71–88) 80 (70 – 87) 78 (73 – 89)
Temperature (°C) 37 (36.7–37.4) 37.0 (36.7–37.4) 37.1 (36.7–37.4)
Headache duration (days) 3 (0.5–7) 2 (1 – 7) 3 (1 – 6)
Visual Analogue Scale (0–10) for pain at ED 8 (6 – 9) 8 (6 – 9) 8 (5 – 10)
Focal-neurological finding 74 (18.9%) 46 (14.6%) 28 (37.3%)
Immediate hospitalization 61 (15.6%) 39 (12.3%) 22 (29.3%)
adata are shown as median (IQR) or n (%)
bclinical scenarios according to Grimaldi et al. [7]
Scenario 1 (worst headache ever): thunderclap-onset headache suggestive for subarachnoidal bleeding
Scenario 2 (fever/neck stiffness): potential meningitis
Scenario 3 (recent worsening) corresponds to tumor or temporal arteriitis
Scenario 4 (history of previous similar headache) corresponds to a primary headache form
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of previous similar headache; OR 0.56, 95%CI 0.32–
0.97), and C-reactive protein (OR 1.31, 95%CI 1.07–1.60;
see also Table 4a). After inclusion of the significant clin-
ical predictors from the univariate analysis along with
copeptin in a multivariate model, only age >50 (OR 2.34,
95% CI 1.41–3.89), focal-neurological findings (OR 3.41,
95% CI 1.94–6.02) and thunderclap onset (OR 2.21, 95%
CI 1.18–4.15) remained associated with the composite
endpoint death or hospitalization, but not copeptin (for
detailed values, see Table 4b). In the second multivariate
model, C-reactive protein (OR 1.27, 95%CI 1.04–1.56)
but not copeptin (OR 1.39 (95%CI 1.0–1.94), p = 0.05),
remained associated with death or hospitalization, (For
detailed values, see Table 4c).
Limitations
We are aware of potential limitations.
First, we included patients with headache irrespective
of the underlying cause or disease. This leads to an in-
homogeneous case mix with small numbers of each
underlying cause, both in benign and in serious second-
ary headaches. However, using broad inclusion criteria
reduces selection bias and, arguably, represents the true
clinical population admitted to an emergency setting
with acute headache.
Second, our gold standard for the final diagnosis of
headache was the clinical diagnosis according to ICHD
criteria after 3 months, verified by a board-certified
neurologist. We abstained from brain imaging due to
organizational and monetary restraints. In patients with-
out brain imaging, there remains a small risk that a cere-
bral pathology may have been missed. However, we
considered it to be rather unlikely that a clinically rele-
vant cerebral pathology would remain unnoticed at
3 months. Moreover this would have introduced a bias
towards the null hypothesis thus underestimating the
real association.
Third, even though we aimed to recruit 24 h per day
and 7 days per week, sampling error is possible, as pa-
tients arriving at night might have been missed by the
staff on duty. Furthermore, this cohort represents an
emergency department population and not the general
headache patient.
Fourth, as copeptin rises after a stress stimulus inde-
pendent from its cause, potential confounding factors
have to be ruled out, such as hypoxia or hypovolemia,
and inflammatory states [38–40].
Discussion
Our main finding is that copeptin was higher in serious
secondary headaches requiring subsequent treatment of
the underlying disease, as compared to benign headache
forms. Importantly, after adjusting for the classical clin-
ical risk factors age >50, sudden onset of headache and
abnormal neurological exam [11], copeptin remained an
independent risk factor for serious secondary headache.
However, the initial hypothesis that copeptin would rule
out serious secondary headache at the predefined cutoff
of 5.0 pmol/L and rule in serious secondary headache at
20 pmol/L with a high sensitivity and specificity could
“as is” not be confirmed. But at a lower cutoff level of
2.5 pmol/L, copeptin had a sensitivity of > 90%.
The most commonly postulated mechanism for the
early copeptin elevation in acute illness is that copeptin
reflects the activation of the hypothalamus-pituitary-
adrenal axis at the hypothalamic level [41]. Copeptin
Table 2 Headache classification
Headache classification (n = 391) n (%)
Primary headache 219 (56.0)
- Primary headache, not classified 38 (9.7)
- Migraine 114 (29.1)
- Tension-type headache 51 (13.0)
- Cluster headache 4 (1.0)
- Trigeminus neuralgia 6 (1.5)
- Medication overuse headache 6 (1.5)
Secondary headache 172 (44.0)
- Not seriousa 97 (24.8)
- Serious: 75 (19.2)
- Subarachnoidal bleeding 8 (2.0)
- Sinus vein thrombosis 7 (1.8)
- Intracerebral bleeding 10 (2.6)
- Cerebral tumor 6 (1.5)
- Cerebral ischemia 6 (1.5)
- Dissection of carotid artery 4 (1.0)
- Temporal arteriitis 3 (0.8)
- Bacterial meningitis 1 (0.3)
- Viral meningoencephalitis 7 (1.8)
- Neuroinflammatory diseaseb 4 (1.0)
- Chronic subdural hematoma 5 (1.3)
- High intracranial pressure 3 (0.8)
- Low intracranial pressure 3 (0.8)
- Hypertensive urgency 1 (0.3)
- Associated with epileptic seizure 5 (1.3)
- Herpes zoster with cranial nerve affection 1 (0.3)
- Acute glaucoma 1 (0.3)
a31 systemic infections, 2 electrolyte disorders, 23 headaches due to teeth,
facial skin or otorhinolaryngologic aetiology, 6 cases of arterial hypertension, 5
muscular headaches, 4 psychosomatic causes, 1 medication side effect, 1
multifactorial headache. 4 residual post-traumatic headaches, 8 hypoliquorrhea
syndromes where no measures were necessary, 1 residual postoperative headache,
7 mild viral meningitis without detection of any pathogen, 1 pseudotumor cerebri
without necessity of intervention, 1 patient each with headache secondary to Bell’s
palsy, Tolosa Hunt syndrome, and polyneuritis cranialis
bNeuritis vestibularis, Miller-Fisher syndrome, clinically isolated syndrome, and
retrobulbar neuritis
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promptly rises in different physical stress situations, cor-
relating with the magnitude of stress [41–43]. Conse-
quently, copeptin has been shown to be useful for an
early rule out of acute myocardial infarction [29] and for
prognosis in acute ischemic stroke [31]. We now show
that copeptin may also be a promising marker for ruling
out serious secondary headaches.
In acute headache with its high burden of disease [44],
no biomarker has been established in clinical routine to
improve discrimination between serious secondary and
benign headache forms, even though fast and early iden-
tification of serious secondary headaches at the ED is
crucial and has remained an unmet clinical need [2].
Algorithms based on clinical features do exist, but are
inconsistently applied; [2] thus, there is room for im-
provement. Some biomarkers have been explored when
specific causes of secondary headache were suspected,
such as D-dimers for ruling-out sinus vein thrombosis
[14]. Furthermore, there have been efforts for
biomarker-guided treatment in migraine, for example by
predicting treatment response to triptans by measuring
levels of calcitonin gene-related peptide or neurokinin A
[22]. Based on our data, copeptin seems to have
potential as a biomarker in unselected patients present-
ing with acute non-traumatic headache to the emer-
gency department.
However, as copeptin rises after stress independent
from its cause, potential confounding factors have to be
ruled out, especially extra-neurologic causes such as sys-
temic inflammation. Further studies seem warranted
which analyze the influence of stress and pain itself on
copeptin values before copeptin may be introduced into
clinical decision-making.
Interestingly, male gender was independently associated
with serious secondary headache in multivariate analysis.
We attribute this finding to the fact that primary head-
ache, especially migraine, is more frequent in women [45].
Even though copeptin has been shown to predict
adverse outcome in various diseases [46, 47], there was
only a trend for the association with the combined end-
point of death or hospitalization in this study after
adjusting for all other relevant risk factors. Copeptin was
not associated with mortality or hospitalization in multi-
variate analysis. When looking only at mortality, copep-
tin levels were higher in nonsurvivors as compared to
survivors. However, due to the very small number of
nonsurvivors (n = 2), this finding needs further evalu-
ation in larger cohorts.
Copeptin seems therefore not to be an ideal marker to
identify patients in need for hospitalization, probably be-
cause there are other factors contributing to hospitalization
which are not sufficiently reflected by copeptin levels, such
as psychosocial factors (e.g., need for nursing care, patients’
fears of worsening or uncontrollable pain), comorbidities,
or organizational reasons (observation until further investi-
gations were performed, i.e. at night and on week-ends).
Fig. 2 Boxplot of copeptin values
Table 3 Sensitivity and Specificity of copeptin to predict serious
secondary headache at different cutoffs
Copeptin value Sensitivity (%) Specificity (%)
2.5 pmol/l 91.8 23.3
5.0 pmol/l 64.4 66.7
10.0 pmol/l 27.4 89.9
20.0 pmol/l 12.3 95.3
30.0 pmol/l 5.5 96.5
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The greatest potential of copeptin in the studied set-
ting is to rule out serious headache forms by its high
negative predictive value with a similar accuracy as
the clinical rule based on “red flags”. We speculate
that the reason lies in the non-specific and prompt
elevation of copeptin in stress situations. Besides the
underlying disease in secondary headache forms, pain
itself as a stress stimulus may have contributed to the
increase in copeptin levels. This would explain why
some individual patients with migraine also had very
high copeptin values. So far, there is only data on
copeptin levels in relation to chest pain but not to
other pain stimuli. In chest pain, copeptin levels are
higher in acute myocardial infarction than in extracar-
diac chest pain [29]. Thus, if pain stimuli are rather
small and other relevant stress stimuli are lacking, low
copeptin levels should accurately identify benign head-
ache forms.
Conclusion
Copeptin was independently associated with serious sec-
ondary headache as compared to benign headaches
forms. Copeptin may be a promising novel blood bio-
marker for risk stratification in patients with non-
traumatic headache.
Table 4 Main results: univariate and multivariate analysis of primary and secondary endpoint*
a. Univariate analysis of primary and secondary endpoint
Serious secondary headache Composite endpoint mortality or hospitalization
Predictors OR 95%CI p OR 95%CI p
Copeptin (lna) 2.03 1.52–2.70 <0.0001 1.45 1.12.1.88 0.005
Age > 50 2.83 1.69–4.74 <0.0001 2.77 1.72–4.46 <0.0001
Male gender 2.12 1.27–3.52 0.004 1.41 0.88–2.27 0.150
Focal-neurological symptoms 3.50 1.99–6.14 <0.0001 4.23 2.47–7.24 <0.0001
Thunderclap onset 4.23 2.38–7.52 <0.0001 3.04 1.75–5.29 <0.0001
Scenario 4* 0.46 0.24–0.87 0.018 0.56 0.32–0.97 0.040
D-Dimer (lna) 1.50 1.00–2.27 0.052 1.28 0.87–1.89 0.205
Fibrinogen (lna) 2.95 1.10–7.89 0.031 2.29 0.91–5.80 0.080
C-reactive protein (lna) 1.06 0.87–1.30 0.544 1.31 1.07–1.60 0.010
Leukocyte count (lna) 2.04 1.01–4.13 0.046 0.63 0.34–1.16 0.136
b. Multivariate model 1: Copeptin and clinical variables
Serious secondary headache Composite endpoint mortality or hospitalization
Predictors OR 95%CI Predictors OR 95%CI p
Copeptin (lna) 1.73 1.26–2.40 0.001 1.23 0.91–1.65 0.173
Age > 50 2.25 1.28–3.96 0.005 2.34 1.41–3.89 0.001
Male gender 1.84 1.04–3.26 0.035
Focal-neurological symptoms 2.63 1.40–4.92 0.003 3.41 1.94–6.02 <0.0001
Thunderclap onset 2.90 1.49–5.65 0.002 2.21 1.18–4.15 0.013
Scenario 4b 0.73 0.35–1.50 0.388 0.81 0.43–1.51 0.503
c. Multivariate model 2: Copeptin and laboratory variablesa
Serious secondary headache** Composite endpoint mortality or hospitalization***
Predictors OR 95%CI p OR 95%CI p
Copeptin (ln) 1.80 1.33–2.44 <0.0001 1.39 1.0–1.94 0.050
Fibrinogen (ln) 1.22 0.93–1.61 0.158
Leukocyte count (ln) 1.78 0.82–3.83 0.143
C-reactive protein (ln) 1.27 1.04–1.56 0.021
*n = 75 events for the primary endpoint, n = 94 events for the secondary endpoint
aAll laboratory values were transformed by natural logarithm (ln)
bScenario 4 of Grimaldi et al. [7]: previous headache history presenting with a similar episode
For model 2, we performed a subgroup analysis of **n = 327 and ***n = 279 patients with available values of fibrinogen, leukocyte count, and C-reactive protein
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Appendix
Definition of serious secondary NTH
A serious NTH will require subsequent treatment of the
underlying disease or condition. If untreated, the patient
faces the risk of permanent damage or death.
The following diagnoses were selected from the list of
secondary NTH in the ICHD-II criteria [9] as meeting
the above criterion:
 [G44.81] Headache attributed to cranial or cervical
vascular disorder, i.e. the following:
Headache attributed to
– ischaemic stroke or transient ischaemic attack
– non-traumatic intracranial haemorrhage
– unruptured vascular malformation
– vasculitis
– cerebral venous thrombosis (CVT)
– other intracranial vascular disorder
– Headache or facial or neck pain attributed to
arterial dissection
 [G44.813] Headache attributed to arterial
hypertension, i.e. the following:
Headache attributed to
– phaeochromocytoma






 [G44.82] Headache attributed to non-vascular intra-
cranial disorder, i.e. the following:
– high cerebrospinal fluid pressure
– idiopathic intracranial hypertension (IIH)
– intracranial hypertension secondary to metabolic,
toxic or hormonal causes
– intracranial hypertension secondary to hydrocephalus
– low cerebrospinal fluid pressure
– epileptic seizure
– other non-vascular intracranial disorder
 [G44.82] Headache attributed to non-infectious
inflammatory disease, i.e. the following:
Headache attributed to
– neurosarcoidosis
– aseptic (non-infectious) meningitis
– lymphocytic hypophysitis
– other non-infectious inflammatory disease
 [G44.822] Headache attributed to intracranial
neoplasm
 [G44.4 or G44.83] Headache attributed to a
substance or its withdrawal, i.e. the following:
– Carbon monoxide-induced headache
– Cocaine-induced headache
– Other
 [G44.821] Headache attributed to intracranial
infection
 [G44.84] Headache or facial pain attributed to
disorder of cranium, neck, eyes, ears, nose, sinuses,
teeth, mouth or other facial or cranial structures, i.e.
the following:
– Headache attributed to acute glaucoma
– Other
 [G44.847, G44.848 or G44.85] Cranial neuralgias
and central causes of facial pain, i.e. the following:
– Optic neuritis
– Head or facial pain attributed to acute herpes zoster
– other
Additional file
Additional file 1: Spreadsheet of study data. (XLSX 57 kb)
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